Clinical trial
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate…
NCT00258388 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00258388 |
|---|---|
| Title | Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy |
| Official title | A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | custirsen sodium, docetaxel, prednisone |
| Enrollment | 82 |
| Start date | Sep 28, 2005 |
| Primary completion | Nov 8, 2007 |
| Completion | Jan 18, 2011 |
| First posted | Nov 24, 2005 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: